8-K: Tharimmune Faces Nasdaq Delisting Notice Due to Stockholders' Equity Deficiency

Tharimmune, Inc. received a Nasdaq notice on April 1, 2025, indicating non-compliance with the minimum stockholders' equity requirement for continued listing.

Summary

• Tharimmune, Inc. received a notification from Nasdaq on April 1, 2025, stating that it does not meet the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market.
• The company's stockholders' equity, as reported in its 2024 10-K, is $1,307,642, which is below the required threshold.
• The notice does not immediately affect Tharimmune's listing.
• Tharimmune has 45 days from the notification date to submit a plan to regain compliance.
• The company intends to submit a compliance plan and will explore options to address the deficiency.
• If the plan is accepted, Tharimmune may receive up to 180 days from April 1, 2025, to demonstrate compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the company's failure to meet Nasdaq's minimum stockholders' equity requirement. While there's an opportunity to regain compliance, the situation presents significant challenges and uncertainties.

Positives

• The delisting notice does not have an immediate effect on Tharimmune's listing on the Nasdaq Capital Market.
• Tharimmune has the opportunity to submit a plan to regain compliance with Nasdaq listing rules.
• If the compliance plan is accepted, Tharimmune may be granted up to 180 days to evidence compliance.

Negatives

• Tharimmune's stockholders' equity of $1,307,642 is below the Nasdaq minimum requirement of $2,500,000.
• The company faces the risk of delisting from the Nasdaq Capital Market if it fails to regain compliance.

Risks

• Failure to submit an acceptable compliance plan within 45 days could lead to delisting.
• Even with an accepted plan, Tharimmune may not be able to demonstrate compliance within the 180-day period.
• Delisting from Nasdaq could negatively impact the company's stock price and ability to raise capital.

Future Outlook

Tharimmune intends to submit a compliance plan to Nasdaq within 45 days and will evaluate available options to resolve the deficiency and regain compliance. If the plan is accepted, the company may be granted up to 180 days to evidence compliance.

Management Comments

• Randy Milby, Chief Executive Officer, signed the report on behalf of Tharimmune, Inc.

Industry Context

Delisting notices are not uncommon for companies facing financial difficulties, particularly in the biotechnology sector where research and development costs can be substantial. Companies in similar situations often explore options such as raising capital, restructuring debt, or divesting assets to improve their financial position and regain compliance with listing requirements.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum stockholders' equity required for Nasdaq listing, especially during periods of high R&D spending and limited revenue generation.
• Companies like Citius Pharmaceuticals and Diffusion Pharmaceuticals have faced similar challenges and implemented strategies such as reverse stock splits or capital raises to regain compliance.
• The median stockholders' equity for Nasdaq-listed biotech companies is significantly higher than Tharimmune's reported value, indicating a need for substantial improvement.

Stakeholder Impact

• Shareholders may experience a decline in stock value due to the delisting notice.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital and fund its operations could be negatively impacted.

Next Steps

• Tharimmune must submit a compliance plan to Nasdaq within 45 days of the notification date.
• The company will evaluate available options to resolve the stockholders' equity deficiency.
• Nasdaq will review the compliance plan and determine whether to grant an extension for Tharimmune to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, stockholders' equity, compliance, Tharimmune, listing rule